Muvalaplin - Eli Lilly and Company
Alternative Names: LY-3473329Latest Information Update: 09 Apr 2024
At a glance
- Originator Eli Lilly and Company
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Lipoprotein A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperlipidaemia
Most Recent Events
- 09 Apr 2024 Chemical structure information added
- 14 Mar 2024 Eli Lilly and Company completes a phase II KRAKEN trial in Hyperlipidaemia in Hungary, Netherlands, Germany, China, Brazil, Australia, Japan and USA (NCT05563246)
- 05 Mar 2024 Eli Lilly and Company initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO) (NCT06342596)